Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders
Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it. We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMe...
Gespeichert in:
| Veröffentlicht in: | European neuropsychopharmacology 2023-08, Vol.73, p.75-81 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 81 |
|---|---|
| container_issue | |
| container_start_page | 75 |
| container_title | European neuropsychopharmacology |
| container_volume | 73 |
| creator | Chouchana, Margot Delage, Clément Godin, Ophélia Fontan, Jean- Eudes Bellivier, Frank Gard, Sebastien Aubin, Valérie Belzeaux, Raoul Dubertret, Caroline Haffen, Emmanuel Leboyer, Marion Olie, Emilie Courtet, Philippe Polosan, Mircea Roux, Paul Samalin, Ludovic Schwan, Raymund Lefrere, Antoine Bloch, Vanessa Etain, Bruno Etain, B. Olié, E. Leboyer, M. Llorca, PM Barteau, V. Bensalem, S. Godin, O. Laouamri, H. Souryis, K. Hotier, S. Pelletier, A. Bellivier, F. Etain, B. Hennion, V. Marlinge, E. Aouizerate, B. Desage, A. Gard, S. Courtet, P. Ducasse, D. Molière, F. Olié, E. Gross, G. Schwan, R. Schwitzer, T. Bougerol, T. Pouchon, A. Polosan, M. Passerieux, C. Roux, P. Aubin, V. Cussac, I. Loftus, J. Dubertret, C. Mazer, N. Llorca, PM Samalin, L. Mennetrier, M. Blanc, O. Lacelle, D. Vayssie, M. Lefrere, A. Moreau, E. Pastol, J. Murraccioli, I. Suray, A. Groppi, F. Polomeni, H. |
| description | Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it.
We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio.
The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT – 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) – 0.588*antidepressant co-prescription (yes or no) – 0.357*gender (F = 1.899, p = 0.057, adjusted R2 = 0.11)
Information about plasma lamotrigine C/D ratio were available for only 205 out of the 675 individuals in the database and has been obtained from different laboratories. The representativeness of the included sample may be questionable.
This is the first study providing information on a large sample of individuals with BD regarding factors associated with lamotrigine C/D ratio. This study allows to propose a model of lamotrigine C/D ratio that would deserve further replication. |
| doi_str_mv | 10.1016/j.euroneuro.2023.04.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04190881v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0924977X23000731</els_id><sourcerecordid>2955265079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c454t-dcaad836bd03cd11eb1e863e232f5bdf34dce16f45bef9c054280cac7073be0f3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EotPCK0CWsEh6_Zc4y1FFKdJIbEBiZzn2DfUoEw-2M6hvj4eU2SJZtmV_5x7pHELeU2go0PZ23-ASw3zeGgaMNyAaAPmCbKjqeN2plr0kG-iZqPuu-3FFrlPaA1DJef-aXHElWikV3ZDh3tgcYqpMSsF6k9FVv31-rCZzCDn6n37GyobZ4pyjyT7Mty4krP7eKz-X5fzJu8VMaRUO_hgmEyvnU4gOY3pDXo3lF98-nzfk-_2nb3cP9e7r5y93211thRS5dtYYp3g7OODWUYoDRdVyZJyNcnAjF84ibUchBxx7C1IwBdbYDjo-IIz8hnxc5z6aSR-jP5j4pIPx-mG70-c3ELQHpeiJFvbDyh5j-LVgyvrgk8VpMjOGJWnWS8laCV1f0G5FbQwpRRwvsynocxl6ry9l6HMZxUiXMory3bPJMhzQXXT_0i_AdgWwxHLyGHWyHkvWzke0Wbvg_2vyB4Kponk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2955265079</pqid></control><display><type>article</type><title>Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chouchana, Margot ; Delage, Clément ; Godin, Ophélia ; Fontan, Jean- Eudes ; Bellivier, Frank ; Gard, Sebastien ; Aubin, Valérie ; Belzeaux, Raoul ; Dubertret, Caroline ; Haffen, Emmanuel ; Leboyer, Marion ; Olie, Emilie ; Courtet, Philippe ; Polosan, Mircea ; Roux, Paul ; Samalin, Ludovic ; Schwan, Raymund ; Lefrere, Antoine ; Bloch, Vanessa ; Etain, Bruno ; Etain, B. ; Olié, E. ; Leboyer, M. ; Llorca, PM ; Barteau, V. ; Bensalem, S. ; Godin, O. ; Laouamri, H. ; Souryis, K. ; Hotier, S. ; Pelletier, A. ; Bellivier, F. ; Etain, B. ; Hennion, V. ; Marlinge, E. ; Aouizerate, B. ; Desage, A. ; Gard, S. ; Courtet, P. ; Ducasse, D. ; Molière, F. ; Olié, E. ; Gross, G. ; Schwan, R. ; Schwitzer, T. ; Bougerol, T. ; Pouchon, A. ; Polosan, M. ; Passerieux, C. ; Roux, P. ; Aubin, V. ; Cussac, I. ; Loftus, J. ; Dubertret, C. ; Mazer, N. ; Llorca, PM ; Samalin, L. ; Mennetrier, M. ; Blanc, O. ; Lacelle, D. ; Vayssie, M. ; Lefrere, A. ; Moreau, E. ; Pastol, J. ; Murraccioli, I. ; Suray, A. ; Groppi, F. ; Polomeni, H.</creator><creatorcontrib>Chouchana, Margot ; Delage, Clément ; Godin, Ophélia ; Fontan, Jean- Eudes ; Bellivier, Frank ; Gard, Sebastien ; Aubin, Valérie ; Belzeaux, Raoul ; Dubertret, Caroline ; Haffen, Emmanuel ; Leboyer, Marion ; Olie, Emilie ; Courtet, Philippe ; Polosan, Mircea ; Roux, Paul ; Samalin, Ludovic ; Schwan, Raymund ; Lefrere, Antoine ; Bloch, Vanessa ; Etain, Bruno ; Etain, B. ; Olié, E. ; Leboyer, M. ; Llorca, PM ; Barteau, V. ; Bensalem, S. ; Godin, O. ; Laouamri, H. ; Souryis, K. ; Hotier, S. ; Pelletier, A. ; Bellivier, F. ; Etain, B. ; Hennion, V. ; Marlinge, E. ; Aouizerate, B. ; Desage, A. ; Gard, S. ; Courtet, P. ; Ducasse, D. ; Molière, F. ; Olié, E. ; Gross, G. ; Schwan, R. ; Schwitzer, T. ; Bougerol, T. ; Pouchon, A. ; Polosan, M. ; Passerieux, C. ; Roux, P. ; Aubin, V. ; Cussac, I. ; Loftus, J. ; Dubertret, C. ; Mazer, N. ; Llorca, PM ; Samalin, L. ; Mennetrier, M. ; Blanc, O. ; Lacelle, D. ; Vayssie, M. ; Lefrere, A. ; Moreau, E. ; Pastol, J. ; Murraccioli, I. ; Suray, A. ; Groppi, F. ; Polomeni, H. ; List of FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators ; FACE-BD Clinical Sites and Principal Collaborators in France ; FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators ; FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD)</creatorcontrib><description>Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it.
We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio.
The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT – 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) – 0.588*antidepressant co-prescription (yes or no) – 0.357*gender (F = 1.899, p = 0.057, adjusted R2 = 0.11)
Information about plasma lamotrigine C/D ratio were available for only 205 out of the 675 individuals in the database and has been obtained from different laboratories. The representativeness of the included sample may be questionable.
This is the first study providing information on a large sample of individuals with BD regarding factors associated with lamotrigine C/D ratio. This study allows to propose a model of lamotrigine C/D ratio that would deserve further replication.</description><identifier>ISSN: 0924-977X</identifier><identifier>EISSN: 1873-7862</identifier><identifier>DOI: 10.1016/j.euroneuro.2023.04.005</identifier><identifier>PMID: 38465581</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Anticonvulsants - therapeutic use ; Antidepressive Agents - therapeutic use ; Bilirubin - therapeutic use ; Bipolar disorder ; Bipolar Disorder - drug therapy ; Concentration/dose ratio ; Female ; Humans ; Lamotrigine ; Lamotrigine - therapeutic use ; Life Sciences ; Male ; Plasma level ; Retrospective Studies ; Triazines - therapeutic use</subject><ispartof>European neuropsychopharmacology, 2023-08, Vol.73, p.75-81</ispartof><rights>2023 Elsevier B.V. and ECNP</rights><rights>Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c454t-dcaad836bd03cd11eb1e863e232f5bdf34dce16f45bef9c054280cac7073be0f3</citedby><cites>FETCH-LOGICAL-c454t-dcaad836bd03cd11eb1e863e232f5bdf34dce16f45bef9c054280cac7073be0f3</cites><orcidid>0000-0003-0321-4189 ; 0000-0002-3660-6640 ; 0000-0002-5377-1488 ; 0000-0003-0740-4019 ; 0000-0002-6519-8586 ; 0000-0002-1059-5584 ; 0000-0003-4130-1590 ; 0000-0001-5004-5475 ; 0000-0001-5473-3697 ; 0000-0001-6684-8141 ; 0000-0001-7438-8990</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0924977X23000731$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38465581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04190881$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Chouchana, Margot</creatorcontrib><creatorcontrib>Delage, Clément</creatorcontrib><creatorcontrib>Godin, Ophélia</creatorcontrib><creatorcontrib>Fontan, Jean- Eudes</creatorcontrib><creatorcontrib>Bellivier, Frank</creatorcontrib><creatorcontrib>Gard, Sebastien</creatorcontrib><creatorcontrib>Aubin, Valérie</creatorcontrib><creatorcontrib>Belzeaux, Raoul</creatorcontrib><creatorcontrib>Dubertret, Caroline</creatorcontrib><creatorcontrib>Haffen, Emmanuel</creatorcontrib><creatorcontrib>Leboyer, Marion</creatorcontrib><creatorcontrib>Olie, Emilie</creatorcontrib><creatorcontrib>Courtet, Philippe</creatorcontrib><creatorcontrib>Polosan, Mircea</creatorcontrib><creatorcontrib>Roux, Paul</creatorcontrib><creatorcontrib>Samalin, Ludovic</creatorcontrib><creatorcontrib>Schwan, Raymund</creatorcontrib><creatorcontrib>Lefrere, Antoine</creatorcontrib><creatorcontrib>Bloch, Vanessa</creatorcontrib><creatorcontrib>Etain, Bruno</creatorcontrib><creatorcontrib>Etain, B.</creatorcontrib><creatorcontrib>Olié, E.</creatorcontrib><creatorcontrib>Leboyer, M.</creatorcontrib><creatorcontrib>Llorca, PM</creatorcontrib><creatorcontrib>Barteau, V.</creatorcontrib><creatorcontrib>Bensalem, S.</creatorcontrib><creatorcontrib>Godin, O.</creatorcontrib><creatorcontrib>Laouamri, H.</creatorcontrib><creatorcontrib>Souryis, K.</creatorcontrib><creatorcontrib>Hotier, S.</creatorcontrib><creatorcontrib>Pelletier, A.</creatorcontrib><creatorcontrib>Bellivier, F.</creatorcontrib><creatorcontrib>Etain, B.</creatorcontrib><creatorcontrib>Hennion, V.</creatorcontrib><creatorcontrib>Marlinge, E.</creatorcontrib><creatorcontrib>Aouizerate, B.</creatorcontrib><creatorcontrib>Desage, A.</creatorcontrib><creatorcontrib>Gard, S.</creatorcontrib><creatorcontrib>Courtet, P.</creatorcontrib><creatorcontrib>Ducasse, D.</creatorcontrib><creatorcontrib>Molière, F.</creatorcontrib><creatorcontrib>Olié, E.</creatorcontrib><creatorcontrib>Gross, G.</creatorcontrib><creatorcontrib>Schwan, R.</creatorcontrib><creatorcontrib>Schwitzer, T.</creatorcontrib><creatorcontrib>Bougerol, T.</creatorcontrib><creatorcontrib>Pouchon, A.</creatorcontrib><creatorcontrib>Polosan, M.</creatorcontrib><creatorcontrib>Passerieux, C.</creatorcontrib><creatorcontrib>Roux, P.</creatorcontrib><creatorcontrib>Aubin, V.</creatorcontrib><creatorcontrib>Cussac, I.</creatorcontrib><creatorcontrib>Loftus, J.</creatorcontrib><creatorcontrib>Dubertret, C.</creatorcontrib><creatorcontrib>Mazer, N.</creatorcontrib><creatorcontrib>Llorca, PM</creatorcontrib><creatorcontrib>Samalin, L.</creatorcontrib><creatorcontrib>Mennetrier, M.</creatorcontrib><creatorcontrib>Blanc, O.</creatorcontrib><creatorcontrib>Lacelle, D.</creatorcontrib><creatorcontrib>Vayssie, M.</creatorcontrib><creatorcontrib>Lefrere, A.</creatorcontrib><creatorcontrib>Moreau, E.</creatorcontrib><creatorcontrib>Pastol, J.</creatorcontrib><creatorcontrib>Murraccioli, I.</creatorcontrib><creatorcontrib>Suray, A.</creatorcontrib><creatorcontrib>Groppi, F.</creatorcontrib><creatorcontrib>Polomeni, H.</creatorcontrib><creatorcontrib>List of FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators</creatorcontrib><creatorcontrib>FACE-BD Clinical Sites and Principal Collaborators in France</creatorcontrib><creatorcontrib>FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators</creatorcontrib><creatorcontrib>FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD)</creatorcontrib><title>Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders</title><title>European neuropsychopharmacology</title><addtitle>Eur Neuropsychopharmacol</addtitle><description>Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it.
We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio.
The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT – 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) – 0.588*antidepressant co-prescription (yes or no) – 0.357*gender (F = 1.899, p = 0.057, adjusted R2 = 0.11)
Information about plasma lamotrigine C/D ratio were available for only 205 out of the 675 individuals in the database and has been obtained from different laboratories. The representativeness of the included sample may be questionable.
This is the first study providing information on a large sample of individuals with BD regarding factors associated with lamotrigine C/D ratio. This study allows to propose a model of lamotrigine C/D ratio that would deserve further replication.</description><subject>Anticonvulsants - therapeutic use</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Bilirubin - therapeutic use</subject><subject>Bipolar disorder</subject><subject>Bipolar Disorder - drug therapy</subject><subject>Concentration/dose ratio</subject><subject>Female</subject><subject>Humans</subject><subject>Lamotrigine</subject><subject>Lamotrigine - therapeutic use</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Plasma level</subject><subject>Retrospective Studies</subject><subject>Triazines - therapeutic use</subject><issn>0924-977X</issn><issn>1873-7862</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EotPCK0CWsEh6_Zc4y1FFKdJIbEBiZzn2DfUoEw-2M6hvj4eU2SJZtmV_5x7pHELeU2go0PZ23-ASw3zeGgaMNyAaAPmCbKjqeN2plr0kG-iZqPuu-3FFrlPaA1DJef-aXHElWikV3ZDh3tgcYqpMSsF6k9FVv31-rCZzCDn6n37GyobZ4pyjyT7Mty4krP7eKz-X5fzJu8VMaRUO_hgmEyvnU4gOY3pDXo3lF98-nzfk-_2nb3cP9e7r5y93211thRS5dtYYp3g7OODWUYoDRdVyZJyNcnAjF84ibUchBxx7C1IwBdbYDjo-IIz8hnxc5z6aSR-jP5j4pIPx-mG70-c3ELQHpeiJFvbDyh5j-LVgyvrgk8VpMjOGJWnWS8laCV1f0G5FbQwpRRwvsynocxl6ry9l6HMZxUiXMory3bPJMhzQXXT_0i_AdgWwxHLyGHWyHkvWzke0Wbvg_2vyB4Kponk</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Chouchana, Margot</creator><creator>Delage, Clément</creator><creator>Godin, Ophélia</creator><creator>Fontan, Jean- Eudes</creator><creator>Bellivier, Frank</creator><creator>Gard, Sebastien</creator><creator>Aubin, Valérie</creator><creator>Belzeaux, Raoul</creator><creator>Dubertret, Caroline</creator><creator>Haffen, Emmanuel</creator><creator>Leboyer, Marion</creator><creator>Olie, Emilie</creator><creator>Courtet, Philippe</creator><creator>Polosan, Mircea</creator><creator>Roux, Paul</creator><creator>Samalin, Ludovic</creator><creator>Schwan, Raymund</creator><creator>Lefrere, Antoine</creator><creator>Bloch, Vanessa</creator><creator>Etain, Bruno</creator><creator>Etain, B.</creator><creator>Olié, E.</creator><creator>Leboyer, M.</creator><creator>Llorca, PM</creator><creator>Barteau, V.</creator><creator>Bensalem, S.</creator><creator>Godin, O.</creator><creator>Laouamri, H.</creator><creator>Souryis, K.</creator><creator>Hotier, S.</creator><creator>Pelletier, A.</creator><creator>Bellivier, F.</creator><creator>Etain, B.</creator><creator>Hennion, V.</creator><creator>Marlinge, E.</creator><creator>Aouizerate, B.</creator><creator>Desage, A.</creator><creator>Gard, S.</creator><creator>Courtet, P.</creator><creator>Ducasse, D.</creator><creator>Molière, F.</creator><creator>Olié, E.</creator><creator>Gross, G.</creator><creator>Schwan, R.</creator><creator>Schwitzer, T.</creator><creator>Bougerol, T.</creator><creator>Pouchon, A.</creator><creator>Polosan, M.</creator><creator>Passerieux, C.</creator><creator>Roux, P.</creator><creator>Aubin, V.</creator><creator>Cussac, I.</creator><creator>Loftus, J.</creator><creator>Dubertret, C.</creator><creator>Mazer, N.</creator><creator>Llorca, PM</creator><creator>Samalin, L.</creator><creator>Mennetrier, M.</creator><creator>Blanc, O.</creator><creator>Lacelle, D.</creator><creator>Vayssie, M.</creator><creator>Lefrere, A.</creator><creator>Moreau, E.</creator><creator>Pastol, J.</creator><creator>Murraccioli, I.</creator><creator>Suray, A.</creator><creator>Groppi, F.</creator><creator>Polomeni, H.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-0321-4189</orcidid><orcidid>https://orcid.org/0000-0002-3660-6640</orcidid><orcidid>https://orcid.org/0000-0002-5377-1488</orcidid><orcidid>https://orcid.org/0000-0003-0740-4019</orcidid><orcidid>https://orcid.org/0000-0002-6519-8586</orcidid><orcidid>https://orcid.org/0000-0002-1059-5584</orcidid><orcidid>https://orcid.org/0000-0003-4130-1590</orcidid><orcidid>https://orcid.org/0000-0001-5004-5475</orcidid><orcidid>https://orcid.org/0000-0001-5473-3697</orcidid><orcidid>https://orcid.org/0000-0001-6684-8141</orcidid><orcidid>https://orcid.org/0000-0001-7438-8990</orcidid></search><sort><creationdate>20230801</creationdate><title>Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders</title><author>Chouchana, Margot ; Delage, Clément ; Godin, Ophélia ; Fontan, Jean- Eudes ; Bellivier, Frank ; Gard, Sebastien ; Aubin, Valérie ; Belzeaux, Raoul ; Dubertret, Caroline ; Haffen, Emmanuel ; Leboyer, Marion ; Olie, Emilie ; Courtet, Philippe ; Polosan, Mircea ; Roux, Paul ; Samalin, Ludovic ; Schwan, Raymund ; Lefrere, Antoine ; Bloch, Vanessa ; Etain, Bruno ; Etain, B. ; Olié, E. ; Leboyer, M. ; Llorca, PM ; Barteau, V. ; Bensalem, S. ; Godin, O. ; Laouamri, H. ; Souryis, K. ; Hotier, S. ; Pelletier, A. ; Bellivier, F. ; Etain, B. ; Hennion, V. ; Marlinge, E. ; Aouizerate, B. ; Desage, A. ; Gard, S. ; Courtet, P. ; Ducasse, D. ; Molière, F. ; Olié, E. ; Gross, G. ; Schwan, R. ; Schwitzer, T. ; Bougerol, T. ; Pouchon, A. ; Polosan, M. ; Passerieux, C. ; Roux, P. ; Aubin, V. ; Cussac, I. ; Loftus, J. ; Dubertret, C. ; Mazer, N. ; Llorca, PM ; Samalin, L. ; Mennetrier, M. ; Blanc, O. ; Lacelle, D. ; Vayssie, M. ; Lefrere, A. ; Moreau, E. ; Pastol, J. ; Murraccioli, I. ; Suray, A. ; Groppi, F. ; Polomeni, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c454t-dcaad836bd03cd11eb1e863e232f5bdf34dce16f45bef9c054280cac7073be0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anticonvulsants - therapeutic use</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Bilirubin - therapeutic use</topic><topic>Bipolar disorder</topic><topic>Bipolar Disorder - drug therapy</topic><topic>Concentration/dose ratio</topic><topic>Female</topic><topic>Humans</topic><topic>Lamotrigine</topic><topic>Lamotrigine - therapeutic use</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Plasma level</topic><topic>Retrospective Studies</topic><topic>Triazines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chouchana, Margot</creatorcontrib><creatorcontrib>Delage, Clément</creatorcontrib><creatorcontrib>Godin, Ophélia</creatorcontrib><creatorcontrib>Fontan, Jean- Eudes</creatorcontrib><creatorcontrib>Bellivier, Frank</creatorcontrib><creatorcontrib>Gard, Sebastien</creatorcontrib><creatorcontrib>Aubin, Valérie</creatorcontrib><creatorcontrib>Belzeaux, Raoul</creatorcontrib><creatorcontrib>Dubertret, Caroline</creatorcontrib><creatorcontrib>Haffen, Emmanuel</creatorcontrib><creatorcontrib>Leboyer, Marion</creatorcontrib><creatorcontrib>Olie, Emilie</creatorcontrib><creatorcontrib>Courtet, Philippe</creatorcontrib><creatorcontrib>Polosan, Mircea</creatorcontrib><creatorcontrib>Roux, Paul</creatorcontrib><creatorcontrib>Samalin, Ludovic</creatorcontrib><creatorcontrib>Schwan, Raymund</creatorcontrib><creatorcontrib>Lefrere, Antoine</creatorcontrib><creatorcontrib>Bloch, Vanessa</creatorcontrib><creatorcontrib>Etain, Bruno</creatorcontrib><creatorcontrib>Etain, B.</creatorcontrib><creatorcontrib>Olié, E.</creatorcontrib><creatorcontrib>Leboyer, M.</creatorcontrib><creatorcontrib>Llorca, PM</creatorcontrib><creatorcontrib>Barteau, V.</creatorcontrib><creatorcontrib>Bensalem, S.</creatorcontrib><creatorcontrib>Godin, O.</creatorcontrib><creatorcontrib>Laouamri, H.</creatorcontrib><creatorcontrib>Souryis, K.</creatorcontrib><creatorcontrib>Hotier, S.</creatorcontrib><creatorcontrib>Pelletier, A.</creatorcontrib><creatorcontrib>Bellivier, F.</creatorcontrib><creatorcontrib>Etain, B.</creatorcontrib><creatorcontrib>Hennion, V.</creatorcontrib><creatorcontrib>Marlinge, E.</creatorcontrib><creatorcontrib>Aouizerate, B.</creatorcontrib><creatorcontrib>Desage, A.</creatorcontrib><creatorcontrib>Gard, S.</creatorcontrib><creatorcontrib>Courtet, P.</creatorcontrib><creatorcontrib>Ducasse, D.</creatorcontrib><creatorcontrib>Molière, F.</creatorcontrib><creatorcontrib>Olié, E.</creatorcontrib><creatorcontrib>Gross, G.</creatorcontrib><creatorcontrib>Schwan, R.</creatorcontrib><creatorcontrib>Schwitzer, T.</creatorcontrib><creatorcontrib>Bougerol, T.</creatorcontrib><creatorcontrib>Pouchon, A.</creatorcontrib><creatorcontrib>Polosan, M.</creatorcontrib><creatorcontrib>Passerieux, C.</creatorcontrib><creatorcontrib>Roux, P.</creatorcontrib><creatorcontrib>Aubin, V.</creatorcontrib><creatorcontrib>Cussac, I.</creatorcontrib><creatorcontrib>Loftus, J.</creatorcontrib><creatorcontrib>Dubertret, C.</creatorcontrib><creatorcontrib>Mazer, N.</creatorcontrib><creatorcontrib>Llorca, PM</creatorcontrib><creatorcontrib>Samalin, L.</creatorcontrib><creatorcontrib>Mennetrier, M.</creatorcontrib><creatorcontrib>Blanc, O.</creatorcontrib><creatorcontrib>Lacelle, D.</creatorcontrib><creatorcontrib>Vayssie, M.</creatorcontrib><creatorcontrib>Lefrere, A.</creatorcontrib><creatorcontrib>Moreau, E.</creatorcontrib><creatorcontrib>Pastol, J.</creatorcontrib><creatorcontrib>Murraccioli, I.</creatorcontrib><creatorcontrib>Suray, A.</creatorcontrib><creatorcontrib>Groppi, F.</creatorcontrib><creatorcontrib>Polomeni, H.</creatorcontrib><creatorcontrib>List of FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators</creatorcontrib><creatorcontrib>FACE-BD Clinical Sites and Principal Collaborators in France</creatorcontrib><creatorcontrib>FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators</creatorcontrib><creatorcontrib>FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>European neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chouchana, Margot</au><au>Delage, Clément</au><au>Godin, Ophélia</au><au>Fontan, Jean- Eudes</au><au>Bellivier, Frank</au><au>Gard, Sebastien</au><au>Aubin, Valérie</au><au>Belzeaux, Raoul</au><au>Dubertret, Caroline</au><au>Haffen, Emmanuel</au><au>Leboyer, Marion</au><au>Olie, Emilie</au><au>Courtet, Philippe</au><au>Polosan, Mircea</au><au>Roux, Paul</au><au>Samalin, Ludovic</au><au>Schwan, Raymund</au><au>Lefrere, Antoine</au><au>Bloch, Vanessa</au><au>Etain, Bruno</au><au>Etain, B.</au><au>Olié, E.</au><au>Leboyer, M.</au><au>Llorca, PM</au><au>Barteau, V.</au><au>Bensalem, S.</au><au>Godin, O.</au><au>Laouamri, H.</au><au>Souryis, K.</au><au>Hotier, S.</au><au>Pelletier, A.</au><au>Bellivier, F.</au><au>Etain, B.</au><au>Hennion, V.</au><au>Marlinge, E.</au><au>Aouizerate, B.</au><au>Desage, A.</au><au>Gard, S.</au><au>Courtet, P.</au><au>Ducasse, D.</au><au>Molière, F.</au><au>Olié, E.</au><au>Gross, G.</au><au>Schwan, R.</au><au>Schwitzer, T.</au><au>Bougerol, T.</au><au>Pouchon, A.</au><au>Polosan, M.</au><au>Passerieux, C.</au><au>Roux, P.</au><au>Aubin, V.</au><au>Cussac, I.</au><au>Loftus, J.</au><au>Dubertret, C.</au><au>Mazer, N.</au><au>Llorca, PM</au><au>Samalin, L.</au><au>Mennetrier, M.</au><au>Blanc, O.</au><au>Lacelle, D.</au><au>Vayssie, M.</au><au>Lefrere, A.</au><au>Moreau, E.</au><au>Pastol, J.</au><au>Murraccioli, I.</au><au>Suray, A.</au><au>Groppi, F.</au><au>Polomeni, H.</au><aucorp>List of FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators</aucorp><aucorp>FACE-BD Clinical Sites and Principal Collaborators in France</aucorp><aucorp>FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) collaborators</aucorp><aucorp>FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders</atitle><jtitle>European neuropsychopharmacology</jtitle><addtitle>Eur Neuropsychopharmacol</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>73</volume><spage>75</spage><epage>81</epage><pages>75-81</pages><issn>0924-977X</issn><eissn>1873-7862</eissn><abstract>Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it.
We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio.
The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT – 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) – 0.588*antidepressant co-prescription (yes or no) – 0.357*gender (F = 1.899, p = 0.057, adjusted R2 = 0.11)
Information about plasma lamotrigine C/D ratio were available for only 205 out of the 675 individuals in the database and has been obtained from different laboratories. The representativeness of the included sample may be questionable.
This is the first study providing information on a large sample of individuals with BD regarding factors associated with lamotrigine C/D ratio. This study allows to propose a model of lamotrigine C/D ratio that would deserve further replication.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38465581</pmid><doi>10.1016/j.euroneuro.2023.04.005</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-0321-4189</orcidid><orcidid>https://orcid.org/0000-0002-3660-6640</orcidid><orcidid>https://orcid.org/0000-0002-5377-1488</orcidid><orcidid>https://orcid.org/0000-0003-0740-4019</orcidid><orcidid>https://orcid.org/0000-0002-6519-8586</orcidid><orcidid>https://orcid.org/0000-0002-1059-5584</orcidid><orcidid>https://orcid.org/0000-0003-4130-1590</orcidid><orcidid>https://orcid.org/0000-0001-5004-5475</orcidid><orcidid>https://orcid.org/0000-0001-5473-3697</orcidid><orcidid>https://orcid.org/0000-0001-6684-8141</orcidid><orcidid>https://orcid.org/0000-0001-7438-8990</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0924-977X |
| ispartof | European neuropsychopharmacology, 2023-08, Vol.73, p.75-81 |
| issn | 0924-977X 1873-7862 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04190881v1 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anticonvulsants - therapeutic use Antidepressive Agents - therapeutic use Bilirubin - therapeutic use Bipolar disorder Bipolar Disorder - drug therapy Concentration/dose ratio Female Humans Lamotrigine Lamotrigine - therapeutic use Life Sciences Male Plasma level Retrospective Studies Triazines - therapeutic use |
| title | Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A22%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20associated%20with%20lamotrigine%20concentration/dose%20ratio%20in%20individuals%20with%20bipolar%20disorders&rft.jtitle=European%20neuropsychopharmacology&rft.au=Chouchana,%20Margot&rft.aucorp=List%20of%20FondaMental%20Advanced%20Center%20of%20Expertise%20for%20Bipolar%20Disorders%20(FACE-BD)%20collaborators&rft.date=2023-08-01&rft.volume=73&rft.spage=75&rft.epage=81&rft.pages=75-81&rft.issn=0924-977X&rft.eissn=1873-7862&rft_id=info:doi/10.1016/j.euroneuro.2023.04.005&rft_dat=%3Cproquest_hal_p%3E2955265079%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2955265079&rft_id=info:pmid/38465581&rft_els_id=S0924977X23000731&rfr_iscdi=true |